Increased level of stromal cell-derived factor-1 mRNA in peripheral blood mononuclear cells from children with AIDS-related lymphoma

Cancer Research

Volumn 61, Issue 13, 2001, Pages 5028-5037

  Sei, Shizuko ^a   O'Neill, Dennis P ^a   Yang, Quan En ^a   Stewart, Sean K ^b   Kumagai, Mutsuko ^b   Boler, Anne Marie ^b   Zwerski, Sheryl L ^b   Wood, Lauren V ^b   Venzon, David J ^c   Adde, Melissa A ^d   Magrath, Ian T ^d  

^a SAIC FREDERICK INC   (United States)

^b HIV and AIDS Malignancy Branch   (United States)

^c Biostatistics and Data Management Section   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; STROMAL CELL DERIVED FACTOR 1;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; CHILD; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; SCHOOL CHILD; VIRUS CARCINOGENESIS; VIRUS LOAD;

ADOLESCENT; CHEMOKINES, CXC; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; FEMALE; HERPESVIRUS 4, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; INFANT; LYMPHOID TISSUE; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MALE; RNA, MESSENGER; VIRAL LOAD;

EID: 0035394358     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (102)

1. Occurrence of malignancy in immunodeficiency diseases. A literature review
2. Malignancy as a complication of immunosuppressive therapy
3. Malignant disease in immunodeficient states in man
4. Immunodeficiency and the pathogenesis of non-Hodgkin's lymphoma
5. Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome
6. Immunodeficiency-associated lymphoproliferative disorders
7. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981-1986)
8. AIDS-associated non-Hodgkin lymphoma
9. Histopathologic features of high-grade non-Hodgkins's lymphomas in acquired immunodeficiency syndrome
10. Non-Hodgkin's lymphomas
11. Cancer in human immunodeficiency virus-infected children: A case series from the Children's Cancer Group and the National Cancer Institute
12. Malignant non-Hodgkin's lymphomas in children
13. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas
14. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma
15. Epstein-Barr vires and AIDS-related primary central nervous system lymphoma. Viral detection by immunohistochemistry, RNA in situ hybridization, and polymerase chain reaction
16. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1
17. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry
18. Molecular cloning and structure of a pre-B-cell growth-stimulating factor
19. Signal sequence trap: A cloning strategy for secreted proteins and type I membrane proteins
20. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1
21. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice
22. Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene
23. Genetic restriction of AIDS pathogenesis by an SDF-I chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC)
24. The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection
25. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression
26. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage
27. Genetic acceleration of AIDS progression by a promoter variant of CCR5
28. Rapid progression to AIDS in HIV + individuals with a structural variant of the chemokine receptor CX3CR1
29. Protective effect of CCR5 Δ32 heterozygosity is restricted by SDF-1 genotype in children with HIV-1 infection
30. Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1-infected individuals
31. Identification of a major co-receptor for primary isolates of HIV-1
32. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
33. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection
34. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene
35. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study. Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study
36. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression
37. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression
38. Early protective effect of CCR-5 δ32 heterozygosity on HIV-1 disease progression: Relationship with viral load
39. Impact of heterozygosity for the chemokine receptor CCR5 32-bp-deleted allele on plasma virus load and CD4 T lymphocytes in perinatally human immunodeficiency virus-infected children at 8 years of age
40. HIV-1-infected long-term slow progressors heterozygous for δ32-CCR5 show significantly lower plasma viral load than wildtype slow progressors
41. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation
42. Tumor necrosis factor-α regulation of glucose transporter (GLUT1) mRNA turnover. Contribution of the 3′-untranslated region of the GLUT1 message
43. Post-transcriptional regulation of the GAP-43 gene by specific sequences in the 3′ untranslated region of the mRNA
44. The 3′ untranslated region of a rice α-amylase gene functions as a sugar-dependent mRNA stability determinant
45. A pilot study for the treatment of non-Hodgkin's lymphoma in children with acquired immunodeficiency syndrome
46. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age
47. A Phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection
48. A Phase I/II study of the protease inhibitor indinavir in children with HIV infection
49. Progression of human immunodeficiency virus disease is associated with increasing disruptions within the CD4+ T cell receptor repertoire
50. Quantitative analysis of viral burden in tissues from adults and children with symptomatic human immunodeficiency virus type I infection assessed by polymerase chain reaction
51. Dynamics of virus versus host interaction in children with human immunodeficiency virus type 1 infection
52. Increased human immunodeficiency virus (HIV) type 1 DNA content and quinolinic acid concentration in brain tissues from patients with HIV encephalopathy
53. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4
54. Temporal fluctuations in HIV quasi-species in vivo are not reflected by sequential HIV isolations
55. Feedback regulation of human immunodeficiency virus type 1 expression by the Rev protein
56. Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs
57. Splicing variability in HIV type 1 revealed by quantitative RNA polymerase chain reaction
58. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects down-regulation of viral replication in lymphoid tissue
59. Analysis of human immunodeficiency virus type 1 mRNA splicing patterns during disease progression in peripheral blood mononuclear cells from infected individuals
60. Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system
61. Phenotypic variation in the response to the human immunodeficiency virus among derivatives of the CEM T and WIL-2 B cell lines
62. Expression of human immunodeficiency virus type 1 vif and vpr mRNAs is Rev-dependent and regulated by splicing
63. Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1
64. Human immunodeficiency virus type 1 mRNA expression in peripheral blood cells predicts disease progression independently of the numbers of CD4+ lymphocytes
65. Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort
66. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
67. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time
68. Molecular pathology of acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma
69. Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma
70. Mutations in the coding region of c-myc occur frequently in acquired immuno-deficiency syndrome-associated lymphomas
71. Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: Association with diffuse large-cell subtype
72. Cellular origin of human B-cell lymphomas
73. New therapy explains the fall in AIDS incidence with a substantial rise in number of persons on treatment expected
74. Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS Clinical Trial Group study participants
75. Combination antiretroviral therapy and incidence of AIDS-related malignancies
76. Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center
77. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons
78. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV Cohort Study
79. HIV-1 antigen-specific and-nonspecific B cell responses are sensitive to combination antiretroviral therapy
80. High SDF-1 expression in HIV-1 carriers does not correlate with CD8+ T-cell-mediated suppression of viral replication
81. Human T-cell leukemia virus type 1 Tax protein induces the expression of lymphocyte chemoattractant SDF-1/PBSF
82. Rearrangements of immunoglobulin genes during differentiation and evolution
83. Immunoglobulin gene rearrangements in normal mouse B cells
84. Functional V region formation during in vitro culture of a murine immature B precursor cell line
85. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia
86. Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome
87. Prevalence and growth characteristics of malignant stem cells in B-lineage acute lymphoblastic leukemia
88. Survival of human leukaemic B-cell precursors is supported by stromal cells and cytokines: Association with the expression of bcl-2 protein
89. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
90. Establishment of two Epstein-Barr virus negative Burkitt cell lines from a patient with AIDS and B-cell lymphoma
91. In vitro establishment of AIDS-related lymphoma cell lines: Phenotypic characterization, oncogene and tumor suppressor gene lesions, and heterogeneity in Epstein-Barr virus infection
92. Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat
93. The trans-activator gene of HTLV-III is essential for virus replication
94. The trans-activator gene of the human T cell lymphotropic vires type III is required for replication
95. Cellular uptake of the tat protein from human immunodeficiency virus
96. Human immunodeficiency virus type 1 TAT protein activates B lymphocytes
97. Cutting edge: HIV-1 Tat protein differentially modulates the B cell response of naive, memory, and germinal center B cells
98. C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells
99. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro
100. CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: Role of signal transduction
101. Opposite effects of SDF-1 on human immunodeficiency virus type 1 replication